ArticleBlood advances2023
EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Blood advances · 2026Article
- Review
- Lexicon for Clonal Hematopoiesis in Liquid Biopsy.Clinical and translational science · 2026Article
- Tissue-Equivalents of Lymphoid Clonal Hematopoiesis of Indeterminate Potential (L-CHIP) and Germline-Derived Lymphoproliferations: Possible Caveats for Hematopathologists.Hematological oncology · 2025Article
- Genetic Profiling Reveals the Distinctions Among MTX-Associated DLBCL, EBV-Positive Mucocutaneous Ulcer, and EBV + DLBCL.Cancer science · 2025Article
- Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.Genomics, proteomics & bioinformatics · 2025Article
- Polytypic B cells, monotypic/monoclonal B-cell proliferations, and neoplastic T cells diverge fromHaematologica · 2025Article
- Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.The New England journal of medicine · 2024Article
- The Immunology of DLBCL.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.